The ‘Two-Pin’ technique increases sanitation for multiple dose vial users. They draw with the first pin, and then shoot/inject into the body with a new one. This procedure prevents any residual contaminants that may have remained on the drawing pin from being transferred into the body via the injection site. It also makes injection less painful since the drawing needle is necessarily dulled during passage through the rubber stopper atop the vial. A dulled needle increases injection pain because it doesn’t pierce the body as cleanly as an unused one. The protocol below is followed by AAS users who draw from multiple dose vials, but steps 4 - 8 are routinely disregarded by those users who draw from ampoules (also called ampules) and sachets.
The original brand name of oxandrolone was Anavar, which was marketed in the United States and the Netherlands .   This product was eventually discontinued and replaced in the United States with a new product named Oxandrin, which is the sole remaining brand name for oxandrolone in the United States.   Oxandrolone has also been sold under the brand names Antitriol ( Spain ), Anatrophill ( France ), Lipidex ( Brazil ), Lonavar ( Argentina , Australia , Italy ), Protivar, and Vasorome ( Japan ) among others.     Additional brand names exist for products that are manufactured for the steroid black market. 
Remember, nothing is alleged to--or can have--happened to all of MLB over some one or two seasons: the claim is that PEDs were being used at a slowly but steadily increasing rate (and thus "distorting records") from very roughly 1980 through the present. Were that so, or anything like it, we would expect to see a clear long-term uptrend during this period. But we don't: we see a nearly flat line that, if anything, slopes slightly down. The "boost" just isn't there. But that doesn't seem to stop anyone from talking about it.